.png){kind=icon}
Return
CAR-T cell potency: from structural elements to vector backbone components
.png){kind=icon}
OA
AI
DOI：10.1186/s40364-022-00417-w.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Chimeric antigen receptor (CAR) T cell therapy, in which a patient's own T lymphocytes are engineered to recognize and kill cancer cells, has achieved remarkable success in some hematological malignancies in preclinical and clinical trials, resulting in six FDA-approved CAR-T products currently available in the market. Once equipped with a CAR construct, T cells act as living drugs and recognize and eliminate the target tumor cells in an MHC-independent manner. In this review, we first described all structural modular of CAR in detail, focusing on more recent findings. We then pointed out behind-the-scene elements contributing to CAR expression and reviewed how CAR expression can be drastically affected by the elements embedded in the viral vector backbone.
Keywords:
Chimeric antigen receptor
Cancer immunotherapy
Single-chain variable fragment
Nanobody
Lentiviral vectors
Signal peptide
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
B
IF:
11.5
Papers:
926
Citations:
5.0K
Organization
Cited Papers
.png){kind=icon}
ShareSaveShareSavePercutaneous ethanol treatment of hepatocellular carcinoma (HCC): large volumes for large tumors
PREAI
ShareSaveShareSaveShareSaveShareSave
View more